natgillin/translations-raw huggingface dataset:
A scaffold for repair of cartilage or osteochondral defects comprising coral having at least a first portion of an exposed surface, which first portion is raised with respect to at least a second portion of said exposed surface in said coral, wherein said first portion comprises at least a region, which specifically positions and confines said coral within a site of cartilage repair, wherein a series of hollows are present along the long axis of the scaffold. 
Bioskela za obnovu hrskavice ili popravak osteohondralnih defekata s koraljnim kosturom, koji se sastoji od najmanje jednog segmenta s izloženom površinom, koji je izdignut u odnosu na drugi segment izložene površine koraljnog kostura, pri čemu prvi segment obuhvaća područje koje pozicionira i obrubljuje navedeni koraljni kostur i pri čemu se uzduž duge osi skele nalazi serija šupljina.
The scaffold of claim 3, wherein said polymer coating is permeable. 
Bioskela sukladno zahtjevu 3, pri čemu je navedena obloga od polimera propusna.
The scaffold of claim 3, wherein said polymer coating is discontinuous and optionally in the form of aggregates or particles. 
Bioskela sukladno zahtjevu 3, pri čemu navedeni polimer nije uniforman nego po mogućnosti dolazi u obliku nakupina ili čestica.
The scaffold of claim 3, wherein said polymer comprises a natural polymer comprising, collagen, elastin, silk, hyaluronic acid, chitosan, and any combinations thereof. 
Bioskela sukladno zahtjevu 3, pri čemu navedeni polimer dolazi kao prirodni polimer s kolagenom, elastinom, svilom, hijaluronskom kiselinom, hitozanom ili bilo kojom njihovom kombinacijom.
The scaffold of claim 3, wherein said polymer comprises a synthetic biodegradable polymer. 
Bioskela sukladno zahtjevu 3, pri čemu navedeni polimer dolazi kao sintetički biorazgradivi polimer.
The scaffold of claim 3, wherein said polymer coating comprises a cytokine, a bone morphogenetic protein (BMP), a chelator, a cell population, a therapeutic compound, or an antibiotic, or any combination thereof. 
Bioskela sukladno zahtjevu 3, pri čemu navedena obloga od polimera uključuje citokin, koštani morfogenetski protein (BMP), helator, populaciju stanica, terapeutsko sredstvo, antibiotik ili bilo koju njihovu kombinaciju.
The scaffold of claim 8, wherein said cell population comprises mesenchymal stem cells or osteoblasts or condrocytes or other cells involved in cartilage or osteochondral repair or a combination thereof. 
Bioskela sukladno zahtjevu 8, pri čemu navedena populacija stanica obuhvaća mezenhimalne matične stanice ili osteoblaste ili hondrocite ili druge stanice koje se koriste za obnovu hrskavice ili popravak osteohondralnog defekta, ili neka njihova kombinacija.
The scaffold of claim 8, wherein said therapeutic compound comprises an anti-inflammatory compound, an anti-infective compound, a growth factor, a pro-angiogenic factors or a combination thereof. 
Bioskela sukladno zahtjevu 8, pri čemu terapeutsko sredstvo obuhvaća antiupalno sredstvo, antiinfektivno sredstvo, faktor rasta, proangiogene faktore ili neku njihovu kombinaciju.
The scaffold of claim 11, wherein said cell population comprises mesenchymal stem cells and/or chondrocytes and/or other cells involved in cartilage repair. 
Bioskela sukladno zahtjevu 11, pri čemu navedena populacija stanica obuhvaća mezenhimalne matične stanice i/ili osteoblaste i/ili hondrocite i/ili druge stanice koje se koriste za obnovu hrskavice.
A mouse comprising in its germline genome: 
Miš koji u svojem genomu zametnih stanica sadrži:
the mouse comprises a light chain locus comprising in order: the human Vk1-39 gene segment, the human Vk3-20 gene segment, a human Jk1, a human Jk2, a human Jk3, a human Jk4 and a human Jk5, and wherein the light chain locus comprises a hVk/hJk/mCk junction sequence selected from SEQ ID NOs: 38-49; and/or 
miš sadrži lokus lakog lanca koji sadrži ovim redoslijedom: humani segment gena Vk1-39, humani segment gena Vk3-20, humani Jk1, humani Jk2, humani Jk3, humani Jk4 i humani Jk5, pri čemu lokus lakog lanca sadrži čvorišnu sekvencu hVk/hJk/mCk odabranu iz SEQ ID NO: 38-49; i/ili
the mouse has been immunized. 
miš je imuniziran.
The mouse of claim 1 or 2, wherein the mouse comprises a functional or nonfunctional λ light chain locus. 
Miš prema patentnom zahtjevu 1 ili 2, naznačen time, što miš sadrži funkcionalni ili nefunkcionalni lokus lakog lanca λ.
the cell is an embryonic stem (ES) cell; or 
stanica je embrionalna matična (ES) stanica; ili
the cell is a B cell. 
stanica je B stanica.
A mouse embryo that comprises the ES cell of claim 4(a). 
Mišji embrij koji sadrži ES stanicu prema patentnom zahtjevu 4(a).
generate an antibody; and/or 
dobivanja antitijela; i/ili
make a human bispecific antibody; and/or 
dobivanja humanog bispecifičnog antitijela; i/ili
expressing in a single cell: 
izražavanja u jednoj stanici:
maintaining the cell under conditions sufficient to express a fully human antibody; and isolating the antibody from the cell. 
održavanja stanice u uvjetima koji su prikladni za izražavanje potpuno humanog antitijela; i izoliranja antitijela iz stanice.
A method for making a human bispecific antibody, wherein the method comprises immunizing a mouse according to any one of claims 1 to 3 and making the bispecific antibody using human immunoglobulin variable region sequences of B cells from the mouse, preferably wherein the method further comprises: 
Metoda za dobivanje humanog bispecifičnog antitijela, naznačena time, što se metoda sastoji od imunizacije miša prema bilo kojem patentnom zahtjevu od 1 do 3 i dobivanja bispecifičnog antitijela pomoću sekvenci varijabilne regije humanog imunoglobulina B stanica iz miša, poželjno naznačena time, što se metoda dodatno sastoji od:
employing the nucleotide sequence of (b) in making a bispecific antibody. 
upotrebljavanja nukleotidne sekvence iz (b) u proizvodnji bispecifičnog antitijela.
The method according to claim 11, wherein the method comprises: 
Metoda prema patentnom zahtjevu 11, naznačena time, što se metoda sastoji od:
An antibody or epitope-binding fragment thereof according to either claim 1 or claim 2, characterized in that said antibody or epitope-binding fragment thereof is capable of killing said CD38+ cell by apoptosis in the absence of stroma cells or stroma-derived cytokines. 
navedeni laki lanac sadrži varijabilnu regiju koja ima sekvencu aminokiseline prema SEQ ID No.62. Protutijelo prema zahtjevu 1, naznačeno time što je navedeno protutijelo sposobno ubiti navedenu CD38+ stanicu apoptozom u odsutnosti stromalnih stanica ili citokina izvedenih iz strome.
The conjugate of claim 53, characterized in that said cytotoxic agent is selected from the group consisting of a maytansinoid, a small drug, a prodrug, a taxoid, CC-1065 and a CC-1065 analog. 
Konjugat prema zahtjevu 9, naznačen time što je navedeno citotoksično sredstvo odabrano iz skupine koja sadrži majtanzinoid, mali lijek, derivat tomajmicina, derivat leptomicina, predlijek, taksoid, CC-1065 i analog CC-1065.
The anti-human TSLP receptor antibody according to claim 1, comprising the heavy chain consisting of the amino acid sequence of amino acid numbers 1 to 447 of SEQ ID NO: 1, and the light chain consisting of the amino acid sequence shown by SEQ ID NO. 3. 
Protutijelo protiv ljudskog receptora TSLP u skladu s patentnim zahtjevom 3, naznačeno time što sadrži teški lanac koji se sastoji od aminokiselinskog slijeda s aminokiselinskim brojevima 1 do 447 u SEQ ID NO: 1 i laki lanac koji se sastoji od aminokiselinskog slijeda kojeg prikazuje SEQ ID NO: 3.
An anti-LAG-3 antibody for use in treating a solid tumor in a human patient, wherein the treatment comprises at least one administration cycle, wherein the cycle is a period of eight weeks, wherein for each of the at least one cycles, four doses of the anti-LAG-3 antibody are administered at a dose of 3, 20, 80, or 240 mg and four doses of an anti-PD-1 antibody are administered at a dose of 80 or 240 mg; 
Anti-LAG-3 antitijelo za primjenu u liječenju solidnog tumora kod humanog pacijenta, gdje liječenje obuhvaća najmanje jedan ciklus administracije, gdje ciklus je period od osam tjedana, gdje za svaki od najmanje jednog ciklusa, četiri doze anti-LAG-3 antitijela su administrirane u dozi od 3, 20, 80, ili 240 mg i četiri doze anti-PD-1 antitijela su administrirane u dozi od 80 ili 240 mg;
An anti-PD-1 antibody for use in treating a solid tumor in a human patient, wherein the treatment comprises at least one administration cycle, wherein the cycle is a period of eight weeks, wherein for each of the at least one cycles, four doses of an anti-LAG-3 antibody are administered at a dose of 3, 20, 80, or 240 mg and four doses of the anti-PD-1 antibody are administered at a dose of 80 or 240 mg; 
Anti-PD-1 antitijelo za primjenu u liječenju solidnog tumora kod humanog pacijenta, gdje liječenje obuhvaća najmanje jedan ciklus administracije, gdje ciklus je period od osam tjedana, gdje za svaki od najmanje jednog ciklusa, četiri doze anti-LAG-3 antitijela su administrirane u dozi od 3, 20, 80, ili 240 mg i četiri doze anti-PD-1 antitijela su administrirane u dozi od 80 ili 240 mg; anti-PD-1 antitijelo sadrži
The anti-LAG-3 antibody and/or the anti-PD-1 antibody for use according to any one of claims 1-10, wherein the treatment comprises administration of the anti-PD-1 antibody prior to administration of the anti-LAG-3 antibody. 
Anti-LAG-3 antitijelo i/ili anti-PD-1 antitijelo za primjenu u skladu sa bilo kojim od patentnih zahtjeva 1-10, gdje liječenje obuhvaća administraciju anti-PD-1 antitijela prije administracije anti-LAG-3 antitijela.
The anti-LAG-3 antibody and/or the anti-PD-1 antibody for use according to any one of claims 1-10, wherein the treatment comprises administration of the anti-PD-1 antibody after administration of the anti-LAG-3 antibody. 
Anti-LAG-3 antitijelo i/ili anti-PD-1 antitijelo za primjenu u skladu sa bilo kojim od patentnih zahtjeva 1-10, gdje liječenje obuhvaća administraciju anti-PD-1 antitijela nakon administracije anti-LAG-3 antitijela.
The anti-LAG-3 antibody and/or the anti-PD-1 antibody for use according to any one of claims 1-14, wherein the solid tumor is chosen from melanoma, non-small cell lung cancer (NSCLC), human papilloma virus (HPV)-related tumor, and gastric adenocarcinoma. 
Anti-LAG-3 antitijelo i/ili anti-PD-1 antitijelo za primjenu u skladu sa bilo kojim od patentnih zahtjeva 1-14, gdje solidni tumor je izabran od melanoma, ne-sitnostaničnog raka pluća (non-small cell lung cancer - NSCLC), tumora povezanog sa humanim papiloma virusom (HPV), i želučani adenokarcinom.
instructions for using the anti-LAG-3 antibody and anti-PD-1 antibody according to claim 1. 
uputstva za primjenjivanje anti-LAG-3 antitijela i anti-PD-1 antitijela u skladu sa patentnim zahtjevom 1.
lacks effector function; or 
nema efektornu funkciju; ili
The CD3-binding molecule of any one of claims 1-3, wherein said molecule is a CD3-binding diabody that comprises a first polypeptide chain and a second polypeptide chain, said chains being covalently bonded to one another, wherein: 
CD3-vezujuća molekula prema bilo kojem od patentnih zahtjeva 1-3, naznačena time što navedena molekula je CD3-vezujuće diatijelo koje sadrži prvi polipeptidni lanac i drugi polipeptidni lanac, pri čemu su navedeni lanci kovalentno međusobno vezani, pri čemu:
a domain (A) comprising said CD3-specific VL domain; 
domena (A) koja sadrži navedeni CD3-specifičnu VL domenu;
wherein said domains (A) and (B) do not associate with one another to form an epitope binding site; and 
pri čemu se navedene domene (A) i (B) ne vežu međusobno tako da formiraju mjesto vezanja epitopa; i
a domain (E) comprising said CD3-specific VH domain; and 
domena (E) koja sadrži navedenu CD3-specifičnu VH domenu; i
said domains (A) and (E) associate to form said antigen-binding domain that is capable of immunospecifically binding to both human CD3 and to the CD3 of a non-human mammal; 
navedene domene (A) i (E) se vežu tako da formiraju navedenu antigen-vezujuću domenu koja je sposobna za imunospecifično vezanje za oba, humani CD3 i za CD3 nehumanog sisavca;
said domains (B) and (D) associate to form a binding site that immunospecifically binds to a second epitope, said second epitope being different from the CD3 epitope bound by the antigen-binding domain formed from said association of said domains (A) and (E); and 
navedene domene (B) i (D) se vežu tako da formiraju vezujuće mjesto koje se imunospecifično veže za drugi epitop, pri čemu je navedeni drugi epitop različit od CD3 epitopa vezanog antigen-vezujućom domenom formiranom od navedene veze navedenih domena (A) i (E); i
said domains (C) and (F) are covalently associated together. 
navedene domene (C) i (F) su kovalentno vezane međusobno.
The CD3-binding molecule of claim 11, wherein said molecule is capable of immunospecifically binding to CD3 and to a tumor antigen expressed on a tumor cell, wherein said tumor cell is a tumor cell from a cancer selected from the group consisting of: breast cancer, prostate cancer, gastric cancer, lung cancer, stomach cancer, colon cancer, rectal cancer, pancreatic cancer, liver cancer, ovarian cancer, oral cavity cancer, pharyngeal cancer, esophageal cancer, laryngeal cancer, bone cancer, skin cancer, melanoma, uterine cancer, testicular cancer, bladder cancer, kidney cancer, brain cancer, glioblastoma, thyroid cancer, lymphoma, myeloma, and leukemia. 
CD3-vezujuća molekula prema patentnom zahtjevu 11, naznačena time što navedena molekula je sposobna za imunospecifično vezanje za CD3 i za tumorski antigen eksprimiran na stanici tumora, pri čemu navedena stanica tumora je stanica tumora iz raka izabranog iz grupe koja se sastoji od: raka dojke, raka prostate, raka želudca, raka pluća, raka trbuha, raka debelog crijeva, rektalnog raka, raka gušterače, raka jetre, raka jajnika, raka oralne šupljine, faringealnog raka, raka jednjaka, raka grkljana, raka kosti, raka kože, melanoma, raka materice, testikularnog raka, raka mjehura, raka bubrega, raka mozga, glioblastoma, tiroiodnog raka, limfoma, mijeloma i leukemije.
The CD3-binding molecule of claim 11, wherein said molecule is capable of immunospecifically binding to CD3 and to a cell surface antigen, receptor or receptor ligand, wherein said cell surface antigen, receptor or receptor ligand is HER2/neu, B7-H3, CD20, PSMA, IGF-1R, or Ep-CAM. 
CD3-vezujuća molekula prema patentnom zahtjevu 11, naznačena time što navedena molekula je sposobna za imunospecifično vezanje za CD3 i za antigen, receptor ili receptor ligand na staničnoj površini, pri čemu navedeni antigen, receptor ili receptor ligand na staničnoj površini je HER2/neu, B7-H3, CD20, PSMA, IGF-1R ili Ep-CAM.
The CD3-binding molecule of claim 11, wherein said molecule is capable of immunospecifically binding to CD3 and to a cell surface antigen, receptor or receptor ligand, wherein said cell surface antigen, receptor or receptor ligand is a molecule involved in a T cell - B cell association, wherein said molecule involved in said T cell - B cell association is selected from the group consisting of CD19, CD20, CD22, CD23, CD27, CD32B, CD38, CD40, CD79a, CD79b, CD80, CD86, LFA-I, LFA-3 and CFA-I. 
CD3-vezujuća molekula prema patentnom zahtjevu 11, naznačena time što navedena molekula je sposobna za imunospecifično vezanje za CD3 i za antigen, receptor ili receptor ligand na staničnoj površini, pri čemu navedeni antigen, receptor ili receptor ligand na staničnoj površini je molekula uključena u vezu T stanice - B stanice, pri čemu je navedena molekula uključen u navedenu vezu T stanice - B stanice izabran iz grupe koja se sastoji od CD19, CD20, CD22, CD23, CD27, CD32B, CD38, CD40, CD79a, CD79b, CD80, CD86, LFA-I, LFA-3 i CFA-I.
The CD3-binding molecule or the pharmaceutical composition for the use of claim 17 wherein said autoimmune or inflammatory disease is selected from the group consisting of: type I insulin-dependent diabetes, rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, inflammatory bowel disease, myasthenia gravis, celiac's disease, Sjogren's syndrome, Grave's disease, Crohn's disease, autoimmune hepatitis, psoriasis, psoriatic arthritis, asthma, allergic rhinitis, effects from organ transplantation, or graft vs. host disease (GVHD). 
CD3-vezujuća molekula ili farmaceutska kompozicija za upotrebu prema patentnom zahtjevu 17, naznačena time što navedena autoimuna ili inflamatorna bolest je izabrana iz grupe koja se sastoji od: inzulin ovisnog dijabetesa tip I, reumatoidnog artritisa, sistemskog lupus eritematozisa, multiple skleroze, inflamatorne bolesti crijeva, mijastenije gravis, celijakije, Sjogrenovog sindroma, Gravesove bolesti, Crohnove bolesti, autoimunog hepatitisa, psorijaze, psorijatičkog artritisa, astme, alergijskog rinitisa, efekata transplantacije organa ili bolesti transplanta protiv domaćina (GVHD).
The CD3-binding molecule or the pharmaceutical composition for the use of claim 18 wherein said autoimmune or inflammatory disease is type I insulin-dependent diabetes. 
CD3-vezujuća molekula ili farmaceutska kompozicija za upotrebu prema patentnom zahtjevu 18, naznačena time što navedena autoimuna ili inflamatorna bolest je inzulin ovisan dijabetes tipa I.
reacting a trivalent iron compound and a base inside a vessel (2) until the trivalent iron is completely neutralized, to obtain an iron hydroxide and a salt consisting of the anion of the trivalent iron compound and the cation of the base, 
spoj trovalentnog željeza reagira s bazom u posudi (2) dok se trovalentno željezo posve ne neutralizira, kako bi se dobilo željezni hidroksid i sol koja se sastoji od aniona spoja trovalentnog željeza i kationa baze,
feeding the iron hydroxide and the salt into ceramic membranes (6) to wash the iron hydroxide from the salt in cross-flow, 
željezni hidroksid i sol se dodaje u keramičke membrane (6) radi ispiranja željeznog hidroksida iz soli u poprečnom toku,
feeding the iron hydroxide suspension to a membrane filter press (8) where part of the water is removed, to obtain a panel (10) having a moisture content of less than 77% by weight, 
suspenziju željeznog hidroksida se dodaje to a tijesak s membranskim filtrom (8), gdje se uklanja dio vode, kako bi se dobilo ploču (10) sa sadržajem vlage manjim od 77%, težinski,
positioning the containers inside a refrigeration chamber (14) operating at atmospheric pressure and at temperatures less than 0°C for a time between 24 and 240 hours. 
spremnik se stavlja u rashladnu komoru (14), koja radi na atmosferskom tlaku i na temperaturama ispod 0 °C, u trajanju između 24 i 240 sati.
A method as claimed in claim 1, characterised by positioning the containers inside a refrigeration chamber (14) operating at atmospheric pressure and at temperatures less than 0°C for a time between 24 and 48 hours. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se spremnik stavlja u rashladnu komoru (14), koja radi na atmosferskom tlaku i na temperaturama ispod 0 °C, u trajanju između 24 i 48 sati.
A method as claimed in claim 1, characterised in that the trivalent iron is obtained by starting from a divalent iron compound which is oxidized to trivalent iron during the reaction, by the use of an oxidant blown into the reaction environment. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se trovalentno željezo dobiva počevši od spoja dvovalentnog željeza kojeg se oksidira u trovalentno željezo u reakciji, uz upotrebu oksidansa kojeg se upuhuje u reakcijski okoliš.
A method as claimed in claim 1, characterised in that filtration is carried out to obtain a panel having a moisture content of less than 72% by weight. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što se provodi filtriranje kako bi se dobilo ploču sa sadržajem vlage manjim od 72%, težinski.
a vessel (2) for mixing a trivalent iron compound and a base, to completely neutralize the trivalent iron and obtain an iron hydroxide and a salt consisting of the anion of the trivalent iron compound and the cation of the base, 
posude (2) za miješanje spoja trovalentnog željeza s bazom, radi potpunog neutraliziranja trovalentnog željezo i dobivanja željeznog hidroksida i soli koja se sastoji od aniona spoja trovalentnog željeza i kationa baze,
at least one container (12) for the panel obtained by filtering the iron hydroxide, 
najmanje jednog spremnika (12) za ploču dobivenu filtriranjem željeznog hidroksida,
a refrigeration chamber (14) for the container (12) with the panel contained therein, said chamber operating at atmospheric pressure at temperatures less than 0°C. 
rashladne komore (14) za spremnik (12) s pločom koju sadrži, gdje navedena komora radi na atmosferskom tlaku i na temperaturama ispod 0 °C.
The anti-human TSLP receptor antibody according to claim 1, comprising a heavy chain consisting of the amino acid sequence shown by SEQ ID NO: 1 and a light chain consisting of the amino acid sequence shown by SEQ ID NO: 3. 
Protutijelo protiv ljudskog receptora TSLP u skladu s patentnim zahtjevom 1, naznačeno time što sadrži teški lanac koji se sastoji od aminokiselinskog slijeda kojeg prikazuje SEQ ID NO: 1 i laki lanac koji se sastoji od aminokiselinskog slijeda kojeg prikazuje SEQ ID NO: 3.
The anti-human TSLP receptor antibody according to claim 3, comprising a heavy chain consisting of the amino acid sequence of amino acid numbers 1 to 447 of SEQ ID NO: 1 and a light chain consisting of the amino acid sequence shown by SEQ ID NO. 3. 
Protutijelo protiv ljudskog receptora TSLP u skladu s patentnim zahtjevom 3, naznačeno time što sadrži teški lanac koji se sastoji od aminokiselinskog slijeda s aminokiselinskim brojevima 1 do 447 u SEQ ID NO: 1 i laki lanac koji se sastoji od aminokiselinskog slijeda kojeg prikazuje SEQ ID NO: 3.
A polynucleotide comprising a base sequence encoding the heavy chain variable region of the antibody according to claim 1(1) and a polynucleotide comprising a base sequence encoding the light chain variable region of the antibody according to claim 1(1). 
Polinukleotid, naznačen time što sadrži bazni slijed koji kodira varijabilno područje teškog lanca protutijela u skladu s patentnim zahtjevom 1(1) i polinukleotid koji sadrži bazni slijed koji kodira varijabilno područje lakog lanca protutijela u skladu s patentnim zahtjevom 1(1).
A host cell selected from the group consisting of the following (a) to (d): 
Stanica domaćin, naznačena time što je se bira iz skupine koju čine sljedeće (a) do (d):
a host cell transformed with an expression vector comprising a polynucleotide comprising a base sequence encoding the heavy chain variable region of the anti-human TSLP receptor antibody according to claim 1(1) and a polynucleotide comprising a base sequence encoding the light chain variable region of the antibody; 
stanica domaćin transformirana ekspresijskim vektorom koji sadrži polinukleotid koji sadrži bazni slijed koji kodira varijabilno područje teškog lanca protutijela protiv ljudskog receptora TSLP u skladu s patentnim zahtjevom 1(1) i polinukleotid koji sadrži bazni slijed koji kodira varijabilno područje lakog lanca protutijela;
a host cell transformed with an expression vector comprising a polynucleotide comprising a base sequence encoding the heavy chain variable region of the anti-human TSLP receptor antibody according to claim 1(1) and an expression vector comprising a polynucleotide comprising a base sequence encoding the light chain variable region of the antibody; 
stanica domaćin transformirana ekspresijskim vektorom koji sadrži polinukleotid koji sadrži bazni slijed koji kodira varijabilno područje teškog lanca protutijela protiv ljudskog receptora TSLP u skladu s patentnim zahtjevom 1(1) i ekspresijski vektor koji sadrži polinukleotid koji sadrži bazni slijed koji kodira varijabilno područje lakog lanca protutijela;